KUALA LUMPUR: Malaysia is aiming to become a trusted global contributor in clinical research, says Health Minister Datuk Seri Dr Dzulkefly Ahmad.
Opening the 5th Clinical Research Malaysia Conference 2026, Dzulkefly said the country must strengthen its research ecosystem and regional collaborations as Asia emerges as a growing hub for global clinical trials.
"Malaysia cannot merely be a recipient or candidate for external innovation.
"Instead, Malaysia must carve and shape its own unique footprint on the global map of medical discovery," he said.
Dzulkefly said clinical research is not only important for scientific advancement, but also serves as a bridge for patients to gain earlier access to innovative and potentially life-saving treatments.
"We view this not just as a medical necessity but as a moral imperative to ensure equitable access to health innovation," he said.
He said Malaysia’s clinical research ecosystem is supported by more than 3,200 skilled professionals, with 30% of the principal investigators named in the country’s "role of honour" last year being newly appointed researchers.
"This is a clear sign of successful succession planning and strong institutional support," he said.
Dzulkefly also stressed the need to strengthen infrastructure, governance and research support systems to ensure Malaysia remains competitive in the global clinical trials industry.
"Science without humanity loses its purpose," he said.
He added that clinical research is improving healthcare outcomes while contributing to economic growth and high-value job creation.
"Clinical research is a powerful catalyst for regional prosperity," he said.
Dzulkefly said stronger regional and international collaboration is crucial amid geopolitical uncertainties and rapid changes in global healthcare research.
"No single country can build a resilient world-class ecosystem in isolation.
"Collaboration is no longer a choice. It is a necessity," he said.
